Elucidating adverse drug reactions and underlying molecular mechanisms of ivermectin through pharmacovigilance and multi-omics analysis
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.1938550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Boyi Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical College, Changsha Medical University, Changsha, China. Hauptthemen laut MEDLINE: Ivermectin, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions, Antiparasitic Agents. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The comprehensive safety profile and underlying molecular mechanisms of ivermectin-associated adverse drug reactions (ADRs) remain to be fully elucidated.
Methods
We integrated pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) with network toxicology and transcriptomic validation. Disproportionality analyses were conducted on 1,421 ivermectin-related reports to detect signals at the System Organ Class (SOC) and Preferred Term (PT) levels. Network-based approaches, including protein-protein interaction (PPI) analysis and molecular docking, were employed to identify core toxicity targets, followed by ADMET property prediction.
Results
Significant safety signals emerged for Eye disorders, Nervous system disorders, and General disorders. Frequently reported PTs included asthenia, headache, and pyrexia, alongside notable serious signals such as encephalopathy (ROR = 24.1) and toxic encephalopathy (ROR = 16.18). Network toxicology identified five core targets shared across key SOCs: EGFR, ERBB2, TGFB1, PIK3CA, and HSPG2. KEGG enrichment analysis highlighted pathways related to parasitic diseases, leukocyte migration, and endocrine regulation. Molecular docking confirmed high binding affinity between ivermectin components and EGFR (≤ -8.7 kcal/mol). ADMET predictions indicated elevated risks for genotoxicity, ototoxicity, and skin sensitization.
Conclusion
Ivermectin-associated ADRs manifest across multiple organ systems, which are potentially associated with the modulation of predicted candidate targets including EGFR, ERBB2, TGFB1, PIK3CA, and HSPG2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical College, Changsha Medical University, Changsha, China.
- College of Basic Medical Sciences, Naval Medical University, Shanghai, China.
- Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, Shanxi, China.
- Department of Basic Medical Sciences, Changsha Medical University, Changsha, Hunan, China.
- Hunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Changsha Medical University, Changsha, China.
Zitieren
APA
Liu, B., Chen, X., Wang, Y., Zhang, H., Liang, X., Guan, X., Zhang, W., Han, A., & Chen, D. (2026). Elucidating adverse drug reactions and underlying molecular mechanisms of ivermectin through pharmacovigilance and multi-omics analysis. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1938550
Vancouver
Liu B, Chen X, Wang Y, Zhang H, Liang X, Guan X, et al. Elucidating adverse drug reactions and underlying molecular mechanisms of ivermectin through pharmacovigilance and multi-omics analysis. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1938550
BibTeX
@article{Liu2026,
author = {Liu, Boyi and Chen, Xiaoze and Wang, Yishuo and Zhang, Hao and Liang, Xiao and Guan, Xin and Zhang, Wenchao and Han, Ao and Chen, Danna},
title = {Elucidating adverse drug reactions and underlying molecular mechanisms of ivermectin through pharmacovigilance and multi-omics analysis},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.1938550}
}
EUVIMED